For other functions this contract is for the clinical development of BAL30072, a novel monosulfactam for the treatment of infections caused by multi-drug resistant gram-negative bacterial pathogens.

Ended Definitive Contract Awarded Last action

Contract number
HHSO100201300010C
Awardee
Awarding agency
Obligated
$13,096,576

Award facts

Opportunity
Contract value 15% obligated
  • $13,096,576.00 Current, with exercised options
  • $85,175,444.00 Potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 3 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Switzerland
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00010 · To close this contract in line with far 4.804, to update the contracting officer to devin fitzmaurice. $0
Other Administrative Action 9 -$3,668,862
Other Administrative Action 8 $0
Other Administrative Action 7 $0
Other Administrative Action 6 $0
Other Administrative Action 5 $0
Other Administrative Action 4 $0
Other Administrative Action 3 $0
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Original award $16,765,438
Show all 11

About this award

Written by GovTribe AI ·

This is a definitive cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Basilea Pharmaceutica International Ltd, a biopharmaceutical company based in Switzerland. The $85,175,444 contract supports the clinical development of BAL30072, a novel monosulfactam antibiotic for treating infections caused by multidrug-resistant gram-negative bacterial pathogens. This contract is not set aside for any specific business type. In addition to the prime contract, Basilea has also received federal contract sub-awards and grant sub-awards through the Trustees of Boston University, which focus on developing novel antibiotics targeting high-priority gram-negative pathogens such as carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and multidrug-resistant Pseudomonas aeruginosa. These efforts align with the U.S. government's initiatives to combat antimicrobial resistance and address urgent global health threats.

Quick answers

Who was awarded contract HHSO100201300010C?

HHSO100201300010C was awarded to Basilea Pharmaceutica International Ltd, Allschwil by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on June 19, 2013.

How much is contract HHSO100201300010C worth?

The government has obligated $13,096,576 on HHSO100201300010C. Its potential value, with all options, is $85,175,444.

Was contract HHSO100201300010C competed?

The extent of competition for HHSO100201300010C was full and open competition. The government received 3 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login